BioXcel Therapeutics (NASDAQ:BTAI) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

by · The Cerbat Gem

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.01), FiscalAI reports. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.38 million.

BioXcel Therapeutics Price Performance

BTAI stock traded down $0.07 during midday trading on Friday, hitting $1.14. The stock had a trading volume of 573,930 shares, compared to its average volume of 1,229,785. The firm has a market cap of $30.87 million, a PE ratio of -0.17 and a beta of 0.31. BioXcel Therapeutics has a 12-month low of $1.01 and a 12-month high of $8.08. The company’s 50-day moving average price is $1.29 and its 200 day moving average price is $1.63.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. HC Wainwright cut their price objective on BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Wall Street Zen raised shares of BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. Zacks Research raised shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, March 9th. Rodman & Renshaw initiated coverage on shares of BioXcel Therapeutics in a research note on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $11.00.

Read Our Latest Research Report on BioXcel Therapeutics

Institutional Trading of BioXcel Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after buying an additional 6,120 shares during the period. State Street Corp grew its stake in shares of BioXcel Therapeutics by 19.9% during the 4th quarter. State Street Corp now owns 63,218 shares of the company’s stock valued at $101,000 after buying an additional 10,500 shares during the period. Diversify Wealth Management LLC purchased a new stake in shares of BioXcel Therapeutics during the 2nd quarter valued at $27,000. HRT Financial LP purchased a new stake in shares of BioXcel Therapeutics during the 4th quarter valued at $28,000. Finally, XTX Topco Ltd purchased a new stake in shares of BioXcel Therapeutics during the 2nd quarter valued at $42,000. 30.68% of the stock is owned by hedge funds and other institutional investors.

BioXcel Therapeutics Company Profile

(Get Free Report)

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.

Recommended Stories